Therefore, research on the treatment of dyslipidemia and atherosclerosis with angiopoietin-like 3 and Angptl4-related antibodies has also emerged [39], although such treatment has not yet been widely used in clinical practice. This evidence concerns the gene ANGPTL4 and atherosclerosis.